Anti-CXCL13 antibodies for treating autoimmune diseases and cancer
US12145982B2 · kind B2 · utility
0Cited by
7References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2021 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Jul 9, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/521
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are antibodies or fragments thereof having binding specificity to the human chemokine (C-X-C motif) ligand 13 (CXCL13) protein. In various examples, the antibodies or fragments thereof include a VH and VL CDRs as disclosed herein, or variants thereof. Methods of using the antibodies or fragments thereof for treating autoimmune diseases and disorders are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.